BFLY Current Price $12.20 Price Target $20
I like BFLY here, as it has over $500 million in cash following its merger with Longview, and I like that it is fully expected to be cash-flow positive by 2024.Revenue increased 40.0% to $16.5 million in Q2 2021 from $11.8 million in Q2 2020. The revenue can be traced to both product and subscription revenues. Product revenue increased 30.3% to $13.0 million from $10.0 million last year. That is solid. The company is focused heavily on improving subscriptions, and it is translating to sales. Subscription revenue increased 94.3% to $3.5 million from $1.8 million last year. I see this line of revenue growing sizably in the coming quarters as it becomes a bigger focus of the company. With a half of billion in cash BFLY has significant funds to continue growing their customer base with their innovative cost cutting products. Their Butterfly IQ+ is a handheld ultrasound which is cutting the cost of ultrasounds by over 90%, this opens up the opportunity for the company to expand to developing countries with this amazing cost cutting innovation.
I like BFLY here, as it has over $500 million in cash following its merger with Longview, and I like that it is fully expected to be cash-flow positive by 2024.Revenue increased 40.0% to $16.5 million in Q2 2021 from $11.8 million in Q2 2020. The revenue can be traced to both product and subscription revenues. Product revenue increased 30.3% to $13.0 million from $10.0 million last year. That is solid. The company is focused heavily on improving subscriptions, and it is translating to sales. Subscription revenue increased 94.3% to $3.5 million from $1.8 million last year. I see this line of revenue growing sizably in the coming quarters as it becomes a bigger focus of the company. With a half of billion in cash BFLY has significant funds to continue growing their customer base with their innovative cost cutting products. Their Butterfly IQ+ is a handheld ultrasound which is cutting the cost of ultrasounds by over 90%, this opens up the opportunity for the company to expand to developing countries with this amazing cost cutting innovation.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.